Searching for your content...
Phone
877-269-7890 from 8 AM - 10 PM ET
Contact Cision
Nuvaira, a developer of novel therapeutic strategies to treat obstructive lung diseases, announces two treatment milestones. 200 patients have been treated in the AIRFLOW-3 pivotal trial, the first...
Nuvaira, a developer of novel therapeutic strategies to treat obstructive lung diseases, has announced that 100 patients have been randomized in the FDA pivotal AIRFLOW-3 Clinical Trial. This COPD...
Nuvaira, a developer of novel therapeutic strategies to treat obstructive lung diseases, has announced that Tom Griffin has joined Nuvaira as Chief Financial Officer. Tom Griffin has a 30-year track...
Nuvaira, a developer of novel therapeutic strategies to treat obstructive lung diseases, announced today multiple peer-reviewed publications that provide further evidence of the safety, clinical...
Nuvaira, developer of novel therapeutic strategies to treat obstructive lung diseases, announced the first treatments in the AIRFLOW-3 pivotal trial, the first interventional COPD trial to target...
Nuvaira, developer of novel therapeutic strategies to treat obstructive lung diseases, has received acceptance from the Haute Autorité de Santé (HAS, the French health technology assessment agency)...
Nuvaira, a developer of novel therapeutic medical devices to treat obstructive lung diseases, announced today it has closed a $79 million equity financing led by U.S. Venture Partners, with Endeavour ...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.